Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06620003 · ClinicalTrials.gov registry record · Phase 2

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

A Phase 2 study of Marburg Virus Disease, sponsored by Albert B. Sabin Vaccine Institute.

Active
Registry status
Phase 2
Development phase
200
Enrollment target
7
Study locations

NCT06620003 is a Phase 2 study of Marburg Virus Disease that is active but no longer recruiting, run by Albert B. Sabin Vaccine Institute. The registered enrollment target is 200 participants. The trial reports 7 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06620003, a Phase 2 study of Marburg Virus Disease, is active but no longer recruiting, sponsored by Albert B. Sabin Vaccine Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
7
Study locations

Study Summary

A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

Conditions Studied

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL cAd3-Marburg Vaccine

Study Locations (7)

Illinois

  • Synexus Clinical Research US, Inc. - Chicago
  • Optimal Research; LLC - Peoria

Texas

  • Synexus Clinical Research US; Inc. - Dallas
  • Synexus Clinical Research US, Inc. - San Antonio

Alabama

  • Optimal Research; LLC - Huntsville

Arizona

  • Synexus Clinical Research US, Inc. - Phoenix

Florida

  • Optimal Research; LLC - Melbourne

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-04-14
Est. Completion 2026-10
Phase Phase 2

What the Registry Record Tells You About NCT06620003

The ClinicalTrials.gov registry entry for NCT06620003 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert B. Sabin Vaccine Institute, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Marburg Virus Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06620003 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Texas, Alabama.

Frequently Asked Questions

What is clinical trial NCT06620003 about?

NCT06620003 is a clinical study titled "A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults". A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

What is the current status of trial NCT06620003?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-04-14. Estimated completion is 2026-10.

What conditions does trial NCT06620003 study?

This clinical trial studies the following conditions: Marburg Virus Disease.

What interventions are being tested in trial NCT06620003?

The interventions under investigation include: Placebo (BIOLOGICAL), cAd3-Marburg Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT06620003?

This trial is sponsored by Albert B. Sabin Vaccine Institute, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06620003 being conducted?

This trial has 7 study locations across Alabama, Arizona, Florida, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Marburg Virus Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.